Current Landscape of Immunotherapy in Breast Cancer: A Review

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer

Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., den Eynden, G. V., Baehner, F. L., Penault-Llorca, F. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,142 · see citing works

Immunogenic cell death in cancer and infectious disease

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · see citing works

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · see citing works

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · see citing works

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472 · see citing works

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157 · see citing works

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

Deng, L., Liang, H. L., Burnette, B., Beckett, M., Darga, T. E., Weichselbaum, R. R., & Fu, Y. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,101 · see citing works

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody

Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678 · see citing works

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Eenoo, F. V., Rouas, G., Francis, P. A., Crown, J. P., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,634 · see citing works

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · see citing works

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477 · see citing works

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

Adams, S., Gray, R. J., Demaria, S., Goldstein, L. J., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,301 · see citing works

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Loi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,257 · see citing works

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

Formenti, S. C., & Demaria, S. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,058 · see citing works

Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer

Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,016 · see citing works

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · see citing works

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807 · see citing works

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

Tsao, M., Kerr, K. M., Kockx, M. M., Beasley, M. B., Borczuk, A., Botling, J., Bubendorf, L., Chirieac, L. R., Chen, G., Chou, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.013 · Cited by 805 · see citing works

Role of Local Radiation Therapy in Cancer Immunotherapy

Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 780 · see citing works

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C. T., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 775 · see citing works

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Zacharakis, N., Chinnasamy, H., Black, M. A., Xu, H., Lu, Y., Zheng, Z., Pasetto, A., Langhan, M. M., Shelton, T. E., Prickett, T. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 774 · see citing works

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · see citing works

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Dirix, L. Y., Takács, I., Jérusalem, G., Nikolinakos, P. G., Arkenau, H., Forero, A., Boccia, R. V., Lippman, M. E., Somer, R. A., Šmakal, M., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4537-5 · Cited by 748 · see citing works

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

Lemery, S. J., Keegan, P., & Pazdur, R. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664 · see citing works

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

Stanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 632 · see citing works

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., Laurentiis, M. D., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A. C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 632 · see citing works

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

Salgado, R., Denkert, C., Campbell, C., Savas, P. S., Nuciforo, P. G., Aura, C. M., de Azambuja, E., Eidtmann, H., Ellis, C. E., Baselga, J. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0830 · Cited by 605 · see citing works

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A. L., Alumkal, J. J., Scher, H. I., Chin, K. M., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 556 · see citing works

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Loi, S., Giobbie‐Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H. R., Jérusalem, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30812-x · Cited by 472 · see citing works

Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines

Disis, M. L., Gooley, T. A., Rinn, K. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.171 · Cited by 425 · see citing works

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Rugo, H. S., Delord, J., Im, S., Ott, P. A., Piha-Paul, S. A., Bedard, P. L., Sachdev, J. C., Tourneau, C. L., van Brummelen, E. M. J., Varga, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3452 · Cited by 378 · see citing works

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

Tang, C. Z., Welsh, J. W., de Groot, P. M., Massarelli, E., Chang, J. Y., Hess, K. R., Basu, S., Curran, M. A., Cabanillas, M. E., Subbiah, V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1432 · Cited by 324 · see citing works

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

Dieci, M. V., Mathieu, M. C., Guarneri, V., Conte, P., Delaloge, S., André, F., & Goubar, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv239 · Cited by 310 · see citing works

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

Vonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D. K., Soulières, D., Dorazio, P., Trosko, J. A., Rüter, J., Mariani, G. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0505 · Cited by 301 · see citing works

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Chang, C., Zhang, W., Iizuka, K., Foster, P., Molinero, L. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5152 · Cited by 290 · see citing works

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G. M., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 286 · see citing works

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

Garg, A. D., More, S., Rufo, N., Meçe, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 277 · see citing works

The genomic landscape of breast cancer and its interaction with host immunity

Luen, S. J., Virassamy, B., Savas, P. S., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 273 · see citing works

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Mittendorf, E., Clifton, G. T., Holmes, J. P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu211 · Cited by 248 · see citing works

The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

Ibrahim, E. M., Al‐Foheidi, M., Al-Mansour, M. M., & Kazkaz, G. A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3185-2 · Cited by 245 · see citing works

Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

Knutson, K. L., Schiffman, K., Cheever, M. A., et al. (2002) · PubMed · Cited by 232 · see citing works

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

McArthur, H. L., Diab, A. K., Page, D. B., Yuan, J. D., Solomon, S. B., Sacchini, V., Comstock, C., Durack, J. C., Maybody, M., Sung, J. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0190 · Cited by 230 · see citing works

Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

Taylor, C., Hershman, D. L., Shah, N. D., Suciu‐Foca, N., Petrylak, D. P., Taub, R. N., Vahdat, L. T., Cheng, B., Pegram, M. D., Knutson, K. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0507 · Cited by 213 · see citing works

Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)

Emens, L. A., Braiteh, F. S., Cassier, P. A., Delord, J., Eder, J. P., Fassò, M., Xiao, Y., Wang, Y., Molinero, L. L., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2859 · Cited by 211 · see citing works

Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

Nanda, R., Liu, M., Yau, C. S. F., Asare, S. M., Hylton, N., Veer, L. V., Perlmutter, J., Wallace, A. M., Chien, A. J., Forero, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.506 · Cited by 204 · see citing works

Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

Loi, S., Adams, S., Schmid, P., Cortés, J., Cescon, D. W., Winer, E. P., Toppmeyer, D., Rugo, H. S., Laurentiis, M. D., Nanda, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.005 · Cited by 180 · see citing works

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

Gall, V., Philips, A. V., Qiao, N., Clise-Dwyer, K., Perakis, A. A., Zhang, M., Clifton, G. T., Sukhumalchandra, P., Ma, Q., Reddy, S. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2774 · Cited by 156 · see citing works

The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer

Huang, J., Wang, L., Cong, Z., Amoozgar, Z., Kiner, E., Xing, D., Oršulić, S., Matulonis, U. A., & Goldberg, M. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.083 · Cited by 152 · see citing works

Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma

Barker, C. A., Postow, M. A., Khan, S. A., Beal, K. P., Parhar, P. K., Yamada, Y. J., Lee, N. Y., & Wolchok, J. D. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0082 · Cited by 147 · see citing works

Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.

Kono, K., Takahashi, A., Sugai, H., Fujii, H., Choudhury, A., Kiessling, R. W., & Matsumoto, Y. (2002) · PubMed · Cited by 137 · see citing works

Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

Murray, J. L., Gillogly, M., Przepiorka, D., et al. (2002) · PubMed · Cited by 137 · see citing works

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

Mittendorf, E. A., Ardavanis, A. S., Litton, J. K., Shumway, N. M., Hale, D. F., Murray, J. L., Perez, S. A., Ponniah, S., Baxevanis, C. N., Papamichail, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11751 · Cited by 112 · see citing works

Classical pathology and mutational load of breast cancer – integration of two worlds

Budczies, J., Bockmayr, M. L., Denkert, C., Klauschen, F., Lennerz, J. K., Győrffy, B., Dietel, M., Loibl, S., Weichert, W., & Stenzinger, A. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.25 · Cited by 111 · see citing works

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy

Ignatiadis, M., den Eynden, G. V., Salgado, R., Fornili, M., Barèche, Y., Desmedt, C., Rothé, F., Maetens, M., Venet, D., Holgado, E., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy076 · Cited by 93 · see citing works

Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.

Schmid, P., Park, Y. H., Muñoz‐Couselo, E., Kim, S., Sohn, J., Im, S., Holgado, E., Wang, Y., Dang, T. P., Aktan, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.556 · Cited by 89 · see citing works

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

Vinayak, S., Tolaney, S. M., Schwartzberg, L. S., Mita, M. M., McCann, G. A.-L., Tan, A. R., Wahner Hendrickson, A. E., Forero-Torres, A., Anders, C. K., Wulf, G. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1011 · Cited by 77 · see citing works

Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

Tolaney, S., Kalinsky, K. M., Kaklamani, V., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd6-13 · Cited by 71 · see citing works

Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

Loibl, S., Untch, M., Burchardi, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.104 · Cited by 68 · see citing works

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain

Knutson, K. L., Clynes, R., Shreeder, B., Yeramian, P., Kemp, K. P., Ballman, K. V., Tenner, K., Erskine, C. L., Norton, N., Northfelt, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3091 · Cited by 59 · see citing works

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC)

Domchek, S. M., Postel-Vinay, S. C., Bang, Y.-J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-pd6-11 · Cited by 50 · see citing works

Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.

Tolaney, S. M., Kabos, P., Dickler, M. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1059 · Cited by 40 · see citing works

A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).

McArthur, H. L., Barker, C. A., Gucalp, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.14 · Cited by 19 · see citing works

Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.

Pusztai, L., Silber, A. L. M., Hofstatter, E. W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.572 · Cited by 17 · see citing works

Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM)

McArthur, H. L., Beal, K. P., Halpenny, D. F., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-4705 · Cited by 17 · see citing works

Improving risk-stratification of localized prostate cancer in a prospective active surveillance cohort.

Gregg, J. R., Reichard, C. A., Wang, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.104 · Cited by 14 · see citing works

Abstract P2-09-13: Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo)

Molinero, L. L., Chang, C.-W., Udyavar, A., Fassò, M., O'Hear, C. E., Emens, L. A., Cruz, C., Hegde, P., & Schmid, P. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-p2-09-13 · Cited by 5 · see citing works

Estimated Projection of US Cancer Incidence and Death to 2040

Rahib, L., Wehner, M. R., Matrisian, L. M., & Nead, K. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4708 · Cited by 1,339 · see citing works

The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer

Wang, H., Rong, X., Zhao, G., Zhou, Y., Xiao, Y., Ma, D., Jin, X., Wu, Y., Yan, Y., Yang, H., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.010 · Cited by 411 · see citing works

Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade

Gomes-Santos, I. L., Amoozgar, Z., Kumar, A. S., Ho, W. W., Roh, K., Talele, N. P., Curtis, H., Kawaguchi, K., Jain, R. K., & Fukumura, D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0499 · Cited by 181 · see citing works

Immunotherapeutic strategies in breast cancer: a clinical update

Zhang, J. Q., & Plitas, G. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26287 · Cited by 6 · see citing works

Immunometabolism in the tumor microenvironment and its related research progress

Zhang, Z., Hu, Y., Chen, Y., Chen, Z., Zhu, Y., Chen, M., Xia, J., Sun, Y., & Xu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1024789 · Cited by 34 · see citing works

The expression of insulin-like growth factor-1 receptor on LN ( - )breast cancer,LN( + )breast cancer and normal breast tissue

Fan, B. (2004) · Henan yixue yanjiu

Is Breast Cancer Ever Cured? Follow-Up Study of 5623 Breast Cancer Patients

Ciatto, S., & Bonardi, R. (1991) · Tumori Journal · doi:10.1177/030089169107700603 · Cited by 4 · see citing works

MRI of male breast carcinoma

Ahmed, C. M. I. (2020) · Medicine Updates · doi:10.21608/muj.2020.22994.1001

Role of the tumor immune microenvironment in tumor immunotherapy (Review)

Zhou, C., Liu, Q., Xiang, Y., Gou, X., & Li, W. (2021) · Oncology Letters · doi:10.3892/ol.2021.13171 · Cited by 42 · see citing works